223 related articles for article (PubMed ID: 16919461)
1. Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives.
Takahashi T; Sakuraba A; Hirohashi T; Shibata T; Hirose M; Haga Y; Nonoshita K; Kanno T; Ito J; Iwaasa H; Kanatani A; Fukami T; Sato N
Bioorg Med Chem; 2006 Nov; 14(22):7501-11. PubMed ID: 16919461
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists.
Sato N; Takahashi T; Shibata T; Haga Y; Sakuraba A; Hirose M; Sato M; Nonoshita K; Koike Y; Kitazawa H; Fujino N; Ishii Y; Ishihara A; Kanatani A; Fukami T
J Med Chem; 2003 Feb; 46(5):666-9. PubMed ID: 12593644
[TBL] [Abstract][Full Text] [Related]
3. A preliminary study of the metabolic stability of a series of benzoxazinone derivatives as potent neuropeptide Y5 antagonists.
Dordal A; Lipkin M; Macritchie J; Mas J; Port A; Rose S; Salgado L; Savic V; Schmidt W; Serafini MT; Spearing W; Torrens A; Yeste S
Bioorg Med Chem Lett; 2005 Aug; 15(16):3679-84. PubMed ID: 15982873
[TBL] [Abstract][Full Text] [Related]
4. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
Moreno A; Pérez S; Galiano S; Juanenea L; Erviti O; Frígola C; Aldana I; Monge A
Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
Blum CA; Zheng X; De Lombaert S
J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
[TBL] [Abstract][Full Text] [Related]
10. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
[TBL] [Abstract][Full Text] [Related]
11. The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y₂ receptor.
Swanson DM; Wong VD; Jablonowski JA; Shah C; Rudolph DA; Dvorak CA; Seierstad M; Dvorak LK; Morton K; Nepomuceno D; Atack JR; Bonaventure P; Lovenberg TW; Carruthers NI
Bioorg Med Chem Lett; 2011 Sep; 21(18):5552-6. PubMed ID: 21802951
[TBL] [Abstract][Full Text] [Related]
12. Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.
Sato N; Jitsuoka M; Ishikawa S; Nagai K; Tsuge H; Ando M; Okamoto O; Iwaasa H; Gomori A; Ishihara A; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2009 Mar; 19(6):1670-4. PubMed ID: 19233647
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I
Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists.
Zarrinmayeh H; Nunes AM; Ornstein PL; Zimmerman DM; Arnold MB; Schober DA; Gackenheimer SL; Bruns RF; Hipskind PA; Britton TC; Cantrell BE; Gehlert DR
J Med Chem; 1998 Jul; 41(15):2709-19. PubMed ID: 9667962
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
[TBL] [Abstract][Full Text] [Related]
16. Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.
Leslie CP; Bentley J; Biagetti M; Contini S; Di Fabio R; Donati D; Genski T; Guery S; Mazzali A; Merlo G; Pizzi DA; Sacco F; Seri C; Tessari M; Zonzini L; Caberlotto L
Bioorg Med Chem Lett; 2010 Oct; 20(20):6103-7. PubMed ID: 20813523
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and quantitative structure-activity relationships of imidazolylpropylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y1 receptor antagonists.
Dove S; Michel MC; Knieps S; Buschauer A
Can J Physiol Pharmacol; 2000 Feb; 78(2):108-15. PubMed ID: 10737673
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of substituted 4-alkoxy-2-aminopyridines as novel neuropeptide Y1 receptor antagonists.
Sato N; Shibata T; Jitsuoka M; Ohno T; Takahashi T; Hirohashi T; Kanno T; Iwaasa H; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2004 Apr; 14(7):1761-4. PubMed ID: 15026066
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure activity relationship of guanidines as NPY Y5 antagonists.
Aquino CJ; Ramanjulu JM; Heyer D; Daniels AJ; Palazzo F; Dezube M
Bioorg Med Chem; 2004 May; 12(10):2691-708. PubMed ID: 15110851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
